Korea United Pharm will complete patient enrollment of its Phase II trial for the world’s first inhaled COVID-19 treatment ‘Corobin Activair (budesonide+ arformoterol).’

According to the company on the 24th, Korea United Pharm had been enrolling patients for its trial at specialized COVID-19 hospitals in Seoul to assess the safety and efficacy of Corobin Activair in patients with moderate-to-severe COVID-19 since last year.

Korea United Pharm aims to receive conditional approval for its drug within the first half of this year after demonstrating its efficacy and safety in the Phase II trial.

The company had completed manufacturing investigational Corobin Activair for th